T2 Biosystems(US:TTOO)2022-08-18 16:27Investment Highlights - T2 Biosystems' technology platform has a potential initial target market of over $2 billion[6] - The company has a BARDA contract that may fund up to $69 million based on milestones[6, 32, 54, 58] Sepsis Diagnostics - Sepsis contributes to 1 in 5 deaths globally[11] - Sepsis represents $62 billion in U S healthcare costs[15] - Each hour of delayed treatment increases mortality risk nearly 8%[21] - T2 Biosystems' tests provide species and resistance gene identification directly from whole blood within 3-5 hours[24, 27, 55] T2SARS-CoV-2 Test - T2SARS-CoV-2 test has a sensitivity of 95% and a specificity of 100%[30] Financial Performance (Preliminary Q2 2022) - The company's Q2 2022 total revenue is expected to be $5.8 - $6.1 million[69] - The company's Q2 2022 product revenue is expected to be $2.5 - $2.7 million[74] - The company's Q2 2022 R&D revenue is expected to be $3.3 - $3.4 million[77] - The company's cash balance is approximately $14.3 million[83]